Key Highlights

  • SELLAS Life Sciences (NASDAQ:SLS) was trading up 163.69% at USD 19.70 on Tuesday, November 17, 2026, from an implied prior close near USD 7.47 (calculated), after the company reported positive Phase 3 REGAL results in acute myeloid leukemia.
  • The Phase 3 REGAL trial reported median overall survival of 24.0 months with galinpepimut-S against 14.7 months for best available treatment, a hazard ratio of 0.59 and a two-sided p-value of 0.035.
  • The topline analysis came after a prespecified 80 deaths among 126 randomized patients with acute myeloid leukemia in second or later remission who could not undergo a stem cell transplant.
  • The company reported cash and cash equivalents of USD 134.7 million and 203,527,833 shares outstanding at September 30, 2026, with a Biologics License Application planned for the first half of 2027.

Phase 3 REGAL Data Trigger the Surge

SELLAS Life Sciences (NASDAQ:SLS) announced on November 17, 2026 that its pivotal REGAL trial met its overall survival goal. Galinpepimut-S, a Vaccine aimed at the WT1 protein found on leukemia cells, produced a median overall survival of 24.0 months against 14.7 months in the control arm. The hazard ratio of 0.59 equals a 41% lower risk of death, and the p-value of 0.035 cleared the usual 0.05 threshold. Published market data show the shares trading at USD 19.70, up 163.69%, which implies a prior close near USD 7.47 (calculated). The company described the result as statistically significant and clinically meaningful.

What REGAL Tested and Why the Control Arm Matters

REGAL is a randomized, global, open-label study in adults with acute myeloid leukemia who reached a second or later complete remission after salvage therapy and were not candidates for an allogeneic transplant. A total of 126 patients were randomized one to one to the vaccine or to investigator's choice of best available treatment, which could include observation, a hypomethylating agent, venetoclax or low-dose cytarabine. The company said both arms were balanced on prognostic factors, few patients moved on to transplant and the split was even. The vaccine was generally well tolerated, mostly grade 1 or 2 events such as injection-site reactions, with no new safety signals.

Regulatory Path, Cash Position and Risks After a Big Move

Management plans to meet the FDA about an accelerated filing strategy and is preparing a Biologics License Application for the first half of 2027. Secondary and other prespecified analyses are still under way, and the company plans a major medical conference presentation and a Journal paper. SELLAS Life Sciences (NASDAQ:SLS) reported USD 134.7 million of cash and a third-quarter net loss of USD 10.1 million on November 12, 2026, with 203.5 million shares outstanding. At USD 19.70 that is a Market Value near USD 4.0 billion (calculated), far above the USD 1.52 billion in the screener, which was left out as inconsistent. Open-label design, a p-value only slightly under 0.05 and a small sample are the main uncertainties, and regulators may ask for more data. A small number of trades can move such a price and quoted moves can reverse.

Where Things Stand

It rocketed because a pivotal trial turned positive. SELLAS Life Sciences (NASDAQ:SLS) showed 24.0 months of median survival against 14.7 months, a hazard ratio of 0.59 and a p-value of 0.035 in a hard-to-treat leukemia population, so the market repriced the odds of an approval filing. The gain does not settle approval: the FDA must agree on the path, the full data set is still to be presented, and a USD 134.7 million cash balance must fund the filing work. Next items are the FDA meeting, the secondary analyses and any financing announcement after such a large rally.